PCM
LSB

Prelude Capital Management’s LakeShore Biopharma LSB Stock Holding History

Prelude Capital Management’s Portfolio LSB Stock Details LSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-3,220
Closed -$44.4K – 1391
2023
Q2 		$44.4K Buy
+3,220
New +$47.6K ﹤0.01% 980

Other funds holding LSB

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
VAM
Valliance Asset Management Central, Hong Kong $122M AUM 362.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
SLM
Snow Lake Management Menlo Park, California $90.7M AUM 72.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
PAM
Pinpoint Asset Management Hong Kong $576M AUM 43.65% 1-Year Est. Return

Prelude Capital Management's LSB Position: Q3 2023 in Review

Prelude Capital Management sold out of LakeShore Biopharma (LSB) in Q3 2023, closing a stake of 3,220 shares — an estimated $44.4K sold.

Prelude Capital Management first reported a position in LSB in Q2 2023 and held it in 1 quarter. The position peaked at $44.4K in Q2 2023. 12 funds tracked by Wall St. Rank hold LSB as of Q3 2023.

  • Prelude Capital Management reported no remaining LakeShore Biopharma position as of Q3 2023 after selling out during the quarter.
  • Prelude Capital Management sold 3,220 LakeShore Biopharma shares in Q3 2023, an estimated $44.4K.
  • Prelude Capital Management first reported a position in LakeShore Biopharma in Q2 2023 and held it in 1 quarter.
  • Prelude Capital Management's LakeShore Biopharma position peaked at $44.4K in Q2 2023.
  • 12 funds tracked by Wall St. Rank held LakeShore Biopharma as of Q3 2023.

Based on Prelude Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.